New York, NY, March 02, 2023 (GLOBE NEWSWIRE) -- Polaris Market Research has published a new research report titled “Prostate Cancer Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment Therapy; By Distribution Channel; (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) By Region; Segment Forecast, 2023 - 2032” in its research database.
“According to the latest research study, the global prostate cancer treatment market size & share is anticipated to be valued at approximately USD 11.28 Billion in 2022 and is projected to hit a revenue of around USD 23.86 Billion by 2032, at a CAGR of around 7.8% between 2023 and 2032.”
What is Prostate Cancer Treatment? How Big is Prostate Cancer Treatment Market Size & Share?
- Report Overview
Prostate cancer is one of the most common types of cancer in males. In this condition, tissues of the prostate gland develop malignant (cancer) cells. The prostate is found in front of the rectum and below the bladder. Some prostate cancers grow slowly and may require little or no treatment, while some prostate cancers are aggressive and may spread quickly.
One of the common treatments for the condition includes expectant management, surgery, radiation therapy, cryotherapy, chemotherapy, biological therapy, high-intensity focused ultrasound, and hormone therapy. Rise in the incidence of prostate cancer is majorly driving the market growth. Increasing government funding and growing efforts in the public and business sectors to promote treatments for prostate cancer are expected to accelerate the prostate cancer treatment market size.
Request Sample Copy of Prostate Cancer Treatment Market Research Report @ https://www.polarismarketresearch.com/industry-analysis/prostate-cancer-treatment-market/request-for-sample
(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)
Our Sample Report May Includes:
- 2032 Updated Report Introduction, Overview, and In-depth industry analysis.
- 115+ Pages Research Report (Inclusion of Updated Research).
- Provide Chapter-wise guidance on Requests.
- 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
- Includes Updated List of tables & figures.
- Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.
Key Takeaways from The Study
- In-depth analysis, including information about current market drivers and challenges
- Key segments that are likely to register a healthy growth rate are mentioned.
- An exhaustive study on the expected trends, changing dynamics, and market intelligence
- Detailed analysis of the changing competitive scenario and thorough vendor analysis
- It gives a pinpoint investigation of changing rivalry elements and keeps you in front of contenders.
- Conclusive study about the growth plot of the market for forthcoming years.
Some of the Top Market Players Are:
- Ipsen Pharma
- Takeda Pharmaceutical Company Ltd
- Johnson & Johnson
- Indevus Pharmaceuticals
- Bristol-Myers Squibb Company
- AstraZeneca plc
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche AG
- Sanofi S.A.
- Tolmar Inc.
- Bayer AG
- Astellas Pharma Inc.
- Dendreon Pharmaceuticals LLC
- Novartis AG
For Additional Information on Key Players, Download a PDF Brochure: https://www.polarismarketresearch.com/industry-analysis/prostate-cancer-treatment-market/request-for-sample
Market Dynamics
Key Growth Driving Factors
- Development of cost-effective, innovative treatments drives the market growth
The use of novel screening and diagnostic tools is expected to encourage the use of treatments which is boosting the growth of the market. Increased geriatric population, availability of new prostate cancer treatments, and introduction of cost-effective, innovative treatments are some of the key prostate cancer treatment market trends propelling the prostate cancer treatment industry growth. Increased demand for hormonal treatments in the contexts of metastatic prostate cancer that is hormone-naive and non-metastatic castration-resistant (mHNPC) and nmCRPC is supporting the prostate cancer treatment industry growth.
Request for a Discount on this Report Before Purchase @ https://www.polarismarketresearch.com/industry-analysis/prostate-cancer-treatment-market/request-for-discount-pricing
Recent Trends Influencing the Market
Increase in investment by governments and private firms in the healthcare sector to push the industry expansion
- Major businesses operating in the market emphasize creating innovative and cutting-edge products. Numerous businesses have products in their development that are expected to hit the market during the projected period. Merck launched keylynk-010, a trial for testing keytruda and lynparza in patients with metastatic castration-resistant prostate cancer.
- A surge in the number of investments by governments and private institutions in healthcare is one of the key factors augmenting market growth. Further availability of immunotherapies and the development of novel hormonal therapies to prevent cancer is anticipated to boost prostate cancer treatment market demand.
Prostate Cancer Treatment Market: Report Scope
| Report Attribute | Details |
| Revenue forecast in 2032 | USD 23.86 Billion |
| Market size value in 2023 | USD 12.13 Billion |
| Expected CAGR Growth | 7.8% from 2023 – 2032 |
| Base Year | 2021 |
| Forecast Year | 2023 - 2032 |
| Top Market Players | Ipsen Pharma, Takeda Pharmaceutical Company Ltd, Johnson & Johnson, Indevus Pharmaceuticals, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Sanofi S.A., Tolmar Inc., Bayer AG, Astellas Pharma Inc., Dendreon Pharmaceuticals LLC, and Novartis AG. |
| Segments Covered | By Treatment Therapy, By Distribution Channel, By Region |
| Customization Options | Customized purchase options are available to meet any research needs. Explore customized purchase options |
Segmental Analysis
- Hospital pharmacies segment dominated the market
Based on distribution channels, the hospital pharmacies category accounted for the largest prostate cancer treatment market share in 2022 and is anticipated to continue to grow over the forecast period. Hospital pharmacies are convenient for patients. Also, these pharmacies emphasize increasing pharmaceutical sales revenue while aiming to lower the overall cost of prescription drugs. Furthermore, easier accessibility to the internet coupled with increasing public awareness of over-the-counter drugs is estimated to drive the segment growth of the prostate cancer treatment market during the foreseen period.
Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/prostate-cancer-treatment-market/inquire-before-buying
(Inquire about a report quote OR available discount offers to the sales team before purchase.)
Geographic Overview
- North America held the major market share in 2022
In terms of geography, the prostate cancer treatment market in North America accounted for the highest revenue share in 2022 and is likely to maintain its dominance throughout the study period due to the rising demand for prostate cancer treatment goods in the region and the increase in the prevalence of the disease. Also, the launch of potential new drugs in the areas of biologics and hormone therapy is flourishing the regional market growth. For instance, In March 2022, the US FDA approved Pluvicto for an advanced accelerator application that will be used to treat adult patients with prostate cancer.
Browse the Detail Report “Prostate Cancer Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment Therapy; By Distribution Channel; (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) By Region; Segment Forecast, 2023 - 2032” with in-depth TOC: https://www.polarismarketresearch.com/industry-analysis/prostate-cancer-treatment-market
For Additional Information OR Media Enquiry, Please Mail At: sales@polarismarketresearch.com
Recent Developments
- In March 2022, the Pluvicto (Lutetium-177) drug from Novartis has been given FDA approval for the treatment of metastatic, progressing, PSMA-positive prostate cancer.
- In January 2021, the FDA approved Relugolix, a revolutionary drug that is expected to revolutionize the way advanced prostate cancer is treated.
The Key Questions Answered in This Report
- What will be the market size and growth rate in the forecast year?
- What are the key factors driving the industry?
- What are the main trends that are positively impacting the market growth?
- What growth opportunities does the market offer?
- What are the key outcomes of Porter’s five forces model?
- What are the names of key players working in the industry?
- What growth strategies are the companies considering to stay in the market?
Polaris Market Research has segmented the prostate cancer treatment Market report based on treatment therapy, distribution channel, and region:
By Treatment Therapy Outlook
- Chemotherapy
- Systemic Therapy
- Regional Chemotherapy
- Hormonal Therapy
- Anti-Androgens
- LHRH Antagonists
- LHRH Analogs
- Targeted Therapy
- Apoptosis-inducing drugs
- Angiogenesis inhibitor
- Signal transduction inhibitor
- Immunotherapy
- Vaccines
By Distribution Channel Outlook
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Region Outlook
- North America (U.S., Canada)
- Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
- Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
- Latin America (Brazil, Mexico, Argentina)
- Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)
Browse More Related Reports:
- Dravet Syndrome Market: https://www.polarismarketresearch.com/industry-analysis/dravet-syndrome-market
- Brugada Syndrome Market: https://www.polarismarketresearch.com/industry-analysis/brugada-syndrome-market
- Obsessive Compulsion Disorder Drug Market: https://www.polarismarketresearch.com/industry-analysis/obsessive-compulsion-disorder-drug-market
- Nutrition Consulting Services Market: https://www.polarismarketresearch.com/industry-analysis/nutrition-consulting-services-market
- Rabies Veterinary Vaccine Market: https://www.polarismarketresearch.com/industry-analysis/rabies-veterinary-vaccines-market
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.
Contact:
Likhil G
30 Wall Street
8th Floor,
New York City, NY 10005,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
